We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Contrast Agent Enables Low-Dose X-Ray Joint Imaging

By HospiMedica International staff writers
Posted on 10 Apr 2026

X-ray imaging offers limited visualization of soft tissues like cartilage, complicating evaluation of joint pain and degenerative disease. More...

Clinicians often rely on joint-space narrowing as a proxy for cartilage loss, which can be imprecise. Iodine-based contrast agents help but require larger volumes and may pose risks for patients with kidney disease. To help address this challenge, researchers have developed a positively charged contrast agent designed to improve X‑ray visualization of cartilage.

Developed at Northeastern University under the leadership of Ambika Bajpayee, an associate professor of bioengineering, the agent is engineered to leverage the inherent negative charge of soft tissues. The team recently secured a patent for its cationic design, which targets cartilage through electrostatic attraction. By binding to the tissue rather than diffusing away, the agent is designed to improve retention at the site of interest and enable clearer assessment of joint structures using standard radiography.

Soft tissues carry net negative charges due to molecules such as proteins and cell membranes. In cartilage, fixed negative charges also contribute substantially to mechanical properties, supporting restoration of shape after load-bearing. A positively charged contrast agent is drawn into these tissues, where it accumulates and remains available for X‑ray detection more effectively than conventional agents.

The approach aims to address two clinical limitations of current arthrography: poor retention in cartilage because of low perfusion and the need for relatively high injected volumes. According to the developers, imaging with the new method can be performed using approximately 40 times less contrast than usual. The injected agent is absorbed into the joint over about two hours, and it is expected to break down in the body after roughly 24 hours, although additional testing is needed.

Initial studies were conducted in mice, and evaluation in human subjects is anticipated next. If validated clinically, the method could refine radiographic assessment of arthritis by directly enhancing visualization of cartilage rather than relying solely on joint-space measurements.

Related Links
Northeastern University


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Glucose Meter
StatStrip®
Digital Radiography System (Ceiling Free)
Digix CF Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: 4D flow cardiac MRI images of the pulmonary artery in patients with HFpEF. Left: a patient with normal right ventricle function shows laminar blood flow in the pulmonary artery. Right: a patient with right ventricle dysfunction experiencing turbulent blood flow in the artery. (Image Credit: Farhan Raza and Oliver Wieben)

New Multimodal Framework Targets Debilitating Form of Heart Failure

Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricle becomes stiff and thickened despite maintaining a normal ejection fraction. The condition is increasingly common with... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.